| Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents RCA van Linschoten, E Visser, CD Niehot, CJ van Der Woude, ... Alimentary pharmacology & therapeutics 54 (3), 234-248, 2021 | 58 | 2021 |
| Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised … RCA van Linschoten, FM Jansen, RWM Pauwels, LJT Smits, F Atsma, ... The Lancet Gastroenterology & Hepatology 8 (4), 343-355, 2023 | 9 | 2023 |
| Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options AR Bourgonje, RCA van Linschoten, RL West, MA van Dijk, ... Therapeutic advances in gastroenterology 14, 17562848211012595, 2021 | 7 | 2021 |
| Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period RCA van Linschoten, N van Leeuwen, D Nieboer, E Birnie, ... BMJ open 12 (1), e050539, 2022 | 5 | 2022 |
| OP25 prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data R Van Linschoten, N van Leeuwen, JA Hazelzet, CJ van der Woude, ... Journal of Crohn's and Colitis 17 (Supplement_1), i34-i35, 2023 | 3 | 2023 |
| Midline Surface Area of the Corpus Callosum in Children with Attention-deficit/Hyperactivity Disorder: A Systematic Review RCA van Linschoten, D Clydesdale, B Dierckx, SE Mous Erasmus Journal of Medicine 3 (2), 38-42, 2013 | 2 | 2013 |
| Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial FM Jansen, RCA van Linschoten, W Kievit, LJT Smits, RWM Pauwels, ... Journal of Crohn's and Colitis 17 (11), 1771-1780, 2023 | 1 | 2023 |
| Dutch normative data of the sexual distress scale and the body image scale AS Huberts, NJMCV Peeters, ZLR Kaplan, RCA van Linschoten, ... Quality of Life Research 32 (10), 2829-2837, 2023 | 1 | 2023 |
| A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled … RCA van Linschoten, FM Jansen, RWM Pauwels, LJT Smits, F Atsma, ... Digestive Diseases and Sciences, 1-10, 2024 | | 2024 |
| Handling missing values in the analysis of between-hospital differences in ordinal and dichotomous outcomes: a simulation study RCA Van Linschoten, M Amini, N Van Leeuwen, F Eijkenaar, ... BMJ Quality & Safety 32 (12), 742-749, 2023 | | 2023 |
| CastorEDC API: A Python Package for Managing Real World Data in Castor Electronic Data Capture RCA van Linschoten, SL Knijnenburg, RL West, D van Noord Journal of Open Research Software 11 (1), 2023 | | 2023 |
| Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease RCA van Linschoten, AS Huberts, N van Leeuwen, JA Hazelzet, ... Therapeutic Advances in Gastroenterology 16, 17562848231202159, 2023 | | 2023 |
| Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised … RCA van Linschoten, FM Jansen, RWM Pauwels LANCET GASTROENTEROLOGY & HEPATOLOGY 8 (4), E4-E4, 2023 | | 2023 |
| Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID Registry AEM Looijen, RCA van Linschoten, JD Brugma, DJ Hijnen, PHP de Jong, ... JMIR Research Protocols 12 (1), e43230, 2023 | | 2023 |
| P221 Validity of the Self-administered Comorbidity Questionnaire in patients with Inflammatory Bowel Disease R Van Linschoten, AS Huberts, N van Leeuwen, JA Hazelzet, ... Journal of Crohn's and Colitis 17 (Supplement_1), i374-i375, 2023 | | 2023 |
| P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial R Van Linschoten, F Jansen, R Pauwels, L Smits, F Atsma, W Kievit, ... Journal of Crohn's and Colitis 17 (Supplement_1), i655-i657, 2023 | | 2023 |
| Incorrectly analysing stratified and minimised trials may lead to wrongfully rejecting superiority of interventions RCA van Linschoten, R West, D van Noord, N van Leeuwen Gut 71 (5), 1038-1039, 2022 | | 2022 |
| Protocol: Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period RCA van Linschoten, N van Leeuwen, D Nieboer, E Birnie, ... BMJ Open 12 (1), 2022 | | 2022 |
| Cost of inflammatory bowel disease is increasing due to cost of biologicals RCA van Linschoten PharmacoEconomics & Outcomes News 881, 7-26, 2021 | | 2021 |
| P317 Societal cost-of-illness of Inflammatory Bowel Disease has rapidly increased over the years and differs between continents: A systematic review R Van Linschoten, E Visser, C Niehot, J van der Woude, J Hazelzet, ... Journal of Crohn's and Colitis 15 (Supplement_1), S343-S344, 2021 | | 2021 |
Rachel WestGastroenterologist Franciscus Gasthuis&VlietlandGeverifieerd e-mailadres voor franciscus.nl
